Lorcaserin regulatory update

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 10 to discuss an NDA from Arena for lorcaserin to treat obesity. The serotonin (5-HT2C) receptor agonist has a June 27 PDU...